OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
SMYD3 induces sorafenib resistance by activating SMAD2/3-mediated epithelial-mesenchymal transition in hepatocellular carcinoma
Shanshan Wang, Xin You, Xiaoshu Liu, et al.
iScience (2023) Vol. 26, Iss. 7, pp. 106994-106994
Open Access | Times Cited: 8
Shanshan Wang, Xin You, Xiaoshu Liu, et al.
iScience (2023) Vol. 26, Iss. 7, pp. 106994-106994
Open Access | Times Cited: 8
Showing 8 citing articles:
Epithelial–mesenchymal plasticity in cancer: signaling pathways and therapeutic targets
Xiangpeng Wang, Xiaoxia Xue, Mingshi Pang, et al.
MedComm (2024) Vol. 5, Iss. 8
Open Access | Times Cited: 6
Xiangpeng Wang, Xiaoxia Xue, Mingshi Pang, et al.
MedComm (2024) Vol. 5, Iss. 8
Open Access | Times Cited: 6
SMYD3 plays a pivotal role in mediating the epithelial-mesenchymal transition process in breast cancer
Wenwen Zhao, Yuan Gao, Yuting Zhu, et al.
Biochemical and Biophysical Research Communications (2025) Vol. 749, pp. 151363-151363
Closed Access
Wenwen Zhao, Yuan Gao, Yuting Zhu, et al.
Biochemical and Biophysical Research Communications (2025) Vol. 749, pp. 151363-151363
Closed Access
SMYD family in cancer: epigenetic regulation and molecular mechanisms of cancer proliferation, metastasis, and drug resistance
Tae‐Su Han, Dae‐Soo Kim, Mi‐Young Son, et al.
Experimental & Molecular Medicine (2024)
Open Access | Times Cited: 3
Tae‐Su Han, Dae‐Soo Kim, Mi‐Young Son, et al.
Experimental & Molecular Medicine (2024)
Open Access | Times Cited: 3
Strategies to enhance the response of liver cancer to pharmacological treatments
José J.G. Marı́n, Rocı́o I.R. Macı́as, Maitane Asensio, et al.
AJP Cell Physiology (2024) Vol. 327, Iss. 1, pp. C11-C33
Closed Access | Times Cited: 2
José J.G. Marı́n, Rocı́o I.R. Macı́as, Maitane Asensio, et al.
AJP Cell Physiology (2024) Vol. 327, Iss. 1, pp. C11-C33
Closed Access | Times Cited: 2
Mechanisms of sorafenib resistance in hepatocellular carcinoma
Yuanjing Liang
Clinics and Research in Hepatology and Gastroenterology (2024) Vol. 48, Iss. 8, pp. 102434-102434
Closed Access | Times Cited: 2
Yuanjing Liang
Clinics and Research in Hepatology and Gastroenterology (2024) Vol. 48, Iss. 8, pp. 102434-102434
Closed Access | Times Cited: 2
Matrix stiffness-dependent PD-L2 deficiency improves SMYD3/xCT-mediated ferroptosis and the efficacy of anti-PD-1 in HCC
Shunxi Wang, Xiaoxue Yuan, Zetao Yang, et al.
Journal of Advanced Research (2024)
Open Access | Times Cited: 1
Shunxi Wang, Xiaoxue Yuan, Zetao Yang, et al.
Journal of Advanced Research (2024)
Open Access | Times Cited: 1
Silencing MFN2 Drives WNT/β-catenin Nucleation to Reduce Sorafenib Sensitivity in Hepatocellular Carcinoma Cells
Chai-ming Zeng, Bin Shao, Yanping Chen, et al.
Current Medical Science (2024) Vol. 44, Iss. 4, pp. 789-798
Closed Access
Chai-ming Zeng, Bin Shao, Yanping Chen, et al.
Current Medical Science (2024) Vol. 44, Iss. 4, pp. 789-798
Closed Access
Advances in hepatocellular carcinoma drug resistance models
Yien Xiang, Junhua Wu, Hanjiao Qin
Frontiers in Medicine (2024) Vol. 11
Open Access
Yien Xiang, Junhua Wu, Hanjiao Qin
Frontiers in Medicine (2024) Vol. 11
Open Access
